Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
SLAS Discov ; 27(4): 219-228, 2022 06.
Article in English | MEDLINE | ID: mdl-35058188

ABSTRACT

Huntington's disease (HD) is the most common monogenic neurodegenerative disease and is fatal. CAG repeat expansions in mutant Huntingtin (mHTT) exon 1 encode for polyglutamine (polyQ) stretches and influence age of onset and disease severity, depending on their length. mHTT is more structured compared to wild-type (wt) HTT, resulting in a decreased N-terminal conformational flexibility. mHTT inflexibility may contribute to both gain of function toxicity, due to increased mHTT aggregation propensity, but also to loss of function phenotypes, due to decreased interactions with binding partners. High-throughput-screening techniques to identify mHTT flexibility states and potential flexibility modifying small molecules are currently lacking. Here, we propose a novel approach for identifying small molecules that restore mHTT's conformational flexibility in human patient fibroblasts. We have applied a well-established antibody-based time-resolved Förster resonance energy transfer (TR-FRET) immunoassay, which measures endogenous HTT flexibility using two validated HTT-specific antibodies, to a high-throughput screening platform. By performing a small-scale compound screen, we identified several small molecules that can partially rescue mHTT inflexibility, presumably by altering HTT post-translational modifications. Thus, we demonstrated that the HTT TR-FRET immunoassay can be miniaturized and applied to a compound screening workflow in patient cells. This automated assay can now be used in large screening campaigns to identify previously unknown HD drugs and drug targets.


Subject(s)
Huntington Disease , Neurodegenerative Diseases , Fluorescence Resonance Energy Transfer , Humans , Huntingtin Protein/genetics , Huntingtin Protein/metabolism , Huntington Disease/genetics , Mutation , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism
2.
Neurobiol Dis ; 129: 29-37, 2019 09.
Article in English | MEDLINE | ID: mdl-31042572

ABSTRACT

Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disease caused by a CAG expansion, which translates into an elongated polyglutamine (polyQ) repeat near the amino-terminus of the huntingtin protein (HTT). This results in production of a toxic mutant huntingtin protein (mHTT) that leads to neuronal dysfunction and death. Currently, no disease-modifying treatments are available; however, numerous therapeutic strategies aimed at lowering HTT levels in the brain are under development. To date, studies have not closely examined the contribution of mHTT in neurons vs astrocytes to disease pathophysiology. To better understand the role of astrocytes in HD pathophysiology and the need for cell type specific targeting of HTT lowering therapeutic strategies, AAV capsids were employed that selectively transduce neurons, or both neurons and astrocytes. These vectors carrying miRNA sequences directed against HTT were injected into the YAC128 mouse model of HD to selectively lower HTT expression in neurons alone versus neurons and astrocytes. The results suggested that HTT lowering in neurons alone was not sufficient to rescue the motor phenotype in YAC128 mice. Furthermore, HTT lowering in both cell types was required to achieve maximal functional benefit. The study suggested that astrocyte dysfunction may play a critical role in HD pathogenesis, and thus astrocytes represent an important therapeutic target.


Subject(s)
Astrocytes/metabolism , Huntingtin Protein/antagonists & inhibitors , Huntington Disease/metabolism , Animals , Astrocytes/pathology , Brain/metabolism , Brain/pathology , Dependovirus , Disease Models, Animal , Genetic Vectors , Huntingtin Protein/genetics , Huntington Disease/pathology , Mice , Mice, Transgenic , MicroRNAs , Neurons/metabolism , Neurons/pathology , Phenotype , Transduction, Genetic
3.
Mol Ther ; 26(10): 2418-2430, 2018 10 03.
Article in English | MEDLINE | ID: mdl-30057240

ABSTRACT

The present study was designed to characterize transduction of non-human primate brain and spinal cord with a modified adeno-associated virus serotype 2, incapable of binding to the heparan sulfate proteoglycan receptor, referred to as AAV2-HBKO. AAV2-HBKO was infused into the thalamus, intracerebroventricularly or via a combination of both intracerebroventricular and thalamic delivery. Thalamic injection of this modified vector encoding GFP resulted in widespread CNS transduction that included neurons in deep cortical layers, deep cerebellar nuclei, several subcortical regions, and motor neuron transduction in the spinal cord indicative of robust bidirectional axonal transport. Intracerebroventricular delivery similarly resulted in widespread cortical transduction, with one striking distinction that oligodendrocytes within superficial layers of the cortex were the primary cell type transduced. Robust motor neuron transduction was also observed in all levels of the spinal cord. The combination of thalamic and intracerebroventricular delivery resulted in transduction of oligodendrocytes in superficial cortical layers and neurons in deeper cortical layers. Several subcortical regions were also transduced. Our data demonstrate that AAV2-HBKO is a powerful vector for the potential treatment of a wide number of neurological disorders, and highlight that delivery route can significantly impact cellular tropism and pattern of CNS transduction.


Subject(s)
Genetic Therapy , Genetic Vectors/adverse effects , Neurons/drug effects , Parvovirinae/genetics , Spinal Cord/drug effects , Animals , Axonal Transport/drug effects , Brain/drug effects , Brain/pathology , Capsid Proteins/administration & dosage , Capsid Proteins/genetics , Central Nervous System/drug effects , Central Nervous System/pathology , Dependovirus , Disease Models, Animal , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Heparan Sulfate Proteoglycans/administration & dosage , Heparan Sulfate Proteoglycans/genetics , Humans , Infusions, Intraventricular , Motor Neurons/drug effects , Neurons/pathology , Primates , Spinal Cord/pathology , Thalamus/drug effects
4.
Gene Ther ; 25(3): 205-219, 2018 06.
Article in English | MEDLINE | ID: mdl-29785047

ABSTRACT

The successful application of adeno-associated virus (AAV) gene delivery vectors as a therapeutic paradigm will require efficient gene delivery to the appropriate cells in affected organs. In this study, we utilized a rational design approach to introduce modifications to the AAV2 and AAVrh8R capsids and the resulting variants were evaluated for transduction activity in the retina and brain. The modifications disrupted either capsid/receptor binding or altered capsid surface charge. Specifically, we mutated AAV2 amino acids R585A and R588A, which are required for binding to its receptor, heparan sulfate proteoglycans, to generate a variant referred to as AAV2-HBKO. In contrast to parental AAV2, the AAV2-HBKO vector displayed low-transduction activity following intravitreal delivery to the mouse eye; however, following its subretinal delivery, AAV2-HBKO resulted in significantly greater photoreceptor transduction. Intrastriatal delivery of AAV2-HBKO to mice facilitated widespread striatal and cortical expression, in contrast to the restricted transduction pattern of the parental AAV2 vector. Furthermore, we found that altering the surface charge on the AAVrh8R capsid by modifying the number of arginine residues on the capsid surface had a profound impact on subretinal transduction. The data further validate the potential of capsid engineering to improve AAV gene therapy vectors for clinical applications.


Subject(s)
Genetic Therapy/methods , Parvovirinae/growth & development , Parvovirinae/immunology , Animals , Brain/metabolism , Capsid/metabolism , Capsid Proteins/genetics , Capsid Proteins/metabolism , Dependovirus/immunology , Gene Transfer Techniques , Genetic Vectors , HeLa Cells , Heparitin Sulfate , Humans , Mice , Mice, Inbred C57BL , Photoreceptor Cells/metabolism , Retina/metabolism , Transduction, Genetic/methods
5.
Neurobiol Dis ; 76: 24-36, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25583186

ABSTRACT

Huntington Disease (HD) is a progressive neurodegenerative disease caused by an elongated CAG repeat in the huntingtin (HTT) gene that encodes a polyglutamine tract in the HTT protein. Proteolysis of the mutant HTT protein (mHTT) has been detected in human and murine HD brains and is implicated in the pathogenesis of HD. Of particular importance is the site at amino acid (aa) 586 that contains a caspase-6 (Casp6) recognition motif. Activation of Casp6 occurs presymptomatically in human HD patients and the inhibition of mHTT proteolysis at aa586 in the YAC128 mouse model results in the full rescue of HD-like phenotypes. Surprisingly, Casp6 ablation in two different HD mouse models did not completely prevent the generation of this fragment, and therapeutic benefits were limited, questioning the role of Casp6 in the disease. We have evaluated the impact of the loss of Casp6 in the YAC128 mouse model of HD. Levels of the mHTT-586 fragment are reduced but not absent in the absence of Casp6 and we identify caspase 8 as an alternate enzyme that can generate this fragment. In vivo, the ablation of Casp6 results in a partial rescue of body weight gain, normalized IGF-1 levels, a reversal of the depression-like phenotype and decreased HTT levels. In the YAC128/Casp6-/- striatum there is a concomitant reduction in p62 levels, a marker of autophagic activity, suggesting increased autophagic clearance. These results implicate the HTT-586 fragment as a key contributor to certain features of HD, irrespective of the enzyme involved in its generation.


Subject(s)
Caspase 6/metabolism , Huntington Disease/enzymology , Serotonin Plasma Membrane Transport Proteins/metabolism , Animals , Body Weight , Brain-Derived Neurotrophic Factor/metabolism , Caspase 6/genetics , Corpus Striatum/metabolism , Depression/metabolism , Disease Models, Animal , Insulin-Like Growth Factor I/metabolism , Mice , Mice, Transgenic , Motor Activity
6.
Hum Gene Ther ; 25(5): 461-74, 2014 May.
Article in English | MEDLINE | ID: mdl-24484067

ABSTRACT

Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disease caused by an increase in the number of polyglutamine residues in the huntingtin (Htt) protein. With the identification of the underlying basis of HD, therapies are being developed that reduce expression of the causative mutant Htt. RNA interference (RNAi) that seeks to selectively reduce the expression of such disease-causing agents is emerging as a potential therapeutic strategy for this and similar disorders. This study examines the merits of administering a recombinant adeno-associated viral (AAV) vector designed to deliver small interfering RNA (siRNA) that targets the degradation of the Htt transcript. The aim was to lower Htt levels and to correct the behavioral, biochemical, and neuropathological deficits shown to be associated with the YAC128 mouse model of HD. Our data demonstrate that AAV-mediated RNAi is effective at transducing greater than 80% of the cells in the striatum and partially reducing the levels (~40%) of both wild-type and mutant Htt in this region. Concomitant with these reductions are significant improvements in behavioral deficits, reduction of striatal Htt aggregates, and partial correction of the aberrant striatal transcriptional profile observed in YAC128 mice. Importantly, a partial reduction of both the mutant and wild-type Htt levels is not associated with any notable overt neurotoxicity. Collectively, these results support the continued development of AAV-mediated RNAi as a therapeutic strategy for HD.


Subject(s)
Dependovirus/metabolism , Huntington Disease/genetics , Huntington Disease/pathology , Mutant Proteins/genetics , Nerve Tissue Proteins/genetics , RNA Interference , Animals , Behavior, Animal , Disease Models, Animal , HEK293 Cells , Humans , Huntingtin Protein , Mice , Mice, Transgenic , MicroRNAs/metabolism , Neostriatum/metabolism , Neostriatum/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transduction, Genetic
7.
J Huntingtons Dis ; 2(2): 217-28, 2013.
Article in English | MEDLINE | ID: mdl-25063516

ABSTRACT

BACKGROUND: Huntington's disease (HD) is a neurological disorder caused by mutations in the huntingtin (HTT) gene, the product of which leads to selective and progressive neuronal cell death in the striatum and cortex. Transcriptional dysregulation has emerged as a core pathologic feature in the CNS of human and animal models of HD. It is still unclear whether perturbations in gene expression are a consequence of the disease or importantly, contribute to the pathogenesis of HD. OBJECTIVE: To examine if transcriptional dysregulation can be ameliorated with antisense oligonucleotides that reduce levels of mutant Htt and provide therapeutic benefit in the YAC128 mouse model of HD. METHODS: Quantitative real-time PCR analysis was used to evaluate dysregulation of a subset of striatal genes in the YAC128 mouse model. Transcripts were then evaluated following ICV delivery of antisense oligonucleotides (ASO). Rota rod and Porsolt swim tests were used to evaluate phenotypic deficits in these mice following ASO treatment. RESULTS: Transcriptional dysregulation was detected in the YAC128 mouse model and appears to progress with age. ICV delivery of ASOs directed against mutant Htt resulted in reduction in mutant Htt levels and amelioration in behavioral deficits in the YAC128 mouse model. These improvements were correlated with improvements in the levels of several dysregulated striatal transcripts. CONCLUSIONS: The role of transcriptional dysregulation in the pathogenesis of Huntington's disease is not well understood, however, a wealth of evidence now strongly suggests that changes in transcriptional signatures are a prominent feature in the brains of both HD patients and animal models of the disease. Our study is the first to show that a therapeutic agent capable of improving an HD disease phenotype is concomitantly correlated with normalization of a subset of dysregulated striatal transcripts. Our data suggests that correction of these disease-altered transcripts may underlie, at least in part, the therapeutic efficacy shown associated with ASO-mediated correction of HD phenotypes and may provide a novel set of early biomarkers for evaluating future therapeutic concepts for HD.


Subject(s)
Behavior, Animal/drug effects , Gene Expression Regulation/drug effects , Huntington Disease/genetics , Motor Skills/drug effects , Neostriatum/drug effects , Nerve Tissue Proteins/drug effects , Nuclear Proteins/drug effects , Oligonucleotides, Antisense/pharmacology , Animals , Disease Models, Animal , Dopamine and cAMP-Regulated Phosphoprotein 32/drug effects , Dopamine and cAMP-Regulated Phosphoprotein 32/genetics , Enkephalins/drug effects , Enkephalins/genetics , Huntingtin Protein , Hypoxanthine Phosphoribosyltransferase/drug effects , Hypoxanthine Phosphoribosyltransferase/genetics , Infusions, Intraventricular , Mice , Neostriatum/metabolism , Nerve Tissue Proteins/metabolism , Nuclear Proteins/metabolism , Real-Time Polymerase Chain Reaction , Receptor, Cannabinoid, CB1/drug effects , Receptor, Cannabinoid, CB1/genetics , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D1/genetics , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/genetics
8.
Neuron ; 74(6): 1031-44, 2012 Jun 21.
Article in English | MEDLINE | ID: mdl-22726834

ABSTRACT

The primary cause of Huntington's disease (HD) is expression of huntingtin with a polyglutamine expansion. Despite an absence of consensus on the mechanism(s) of toxicity, diminishing the synthesis of mutant huntingtin will abate toxicity if delivered to the key affected cells. With antisense oligonucleotides (ASOs) that catalyze RNase H-mediated degradation of huntingtin mRNA, we demonstrate that transient infusion into the cerebrospinal fluid of symptomatic HD mouse models not only delays disease progression but mediates a sustained reversal of disease phenotype that persists longer than the huntingtin knockdown. Reduction of wild-type huntingtin, along with mutant huntingtin, produces the same sustained disease reversal. Similar ASO infusion into nonhuman primates is shown to effectively lower huntingtin in many brain regions targeted by HD pathology. Rather than requiring continuous treatment, our findings establish a therapeutic strategy for sustained HD disease reversal produced by transient ASO-mediated diminution of huntingtin synthesis.


Subject(s)
Huntington Disease/therapy , Nerve Tissue Proteins/antagonists & inhibitors , Nuclear Proteins/antagonists & inhibitors , Oligodeoxyribonucleotides, Antisense/therapeutic use , Animals , Corpus Striatum/metabolism , Corpus Striatum/pathology , Disease Models, Animal , Disease Progression , Huntingtin Protein , Huntington Disease/genetics , Huntington Disease/pathology , Infusions, Spinal , Macaca mulatta , Mice , Nerve Tissue Proteins/biosynthesis , Nerve Tissue Proteins/genetics , Neurons/metabolism , Neurons/pathology , Nuclear Proteins/biosynthesis , Nuclear Proteins/genetics , Oligodeoxyribonucleotides, Antisense/administration & dosage , Time , Treatment Outcome
9.
Hum Mol Genet ; 21(10): 2219-32, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22328089

ABSTRACT

The development of animal models of Huntington disease (HD) has enabled studies that help define the molecular aberrations underlying the disease. The BACHD and YAC128 transgenic mouse models of HD harbor a full-length mutant huntingtin (mHTT) and recapitulate many of the behavioural and neuropathological features of the human condition. Here, we demonstrate that while BACHD and YAC128 animals exhibit similar deficits in motor learning and coordination, depressive-like symptoms, striatal volume loss and forebrain weight loss, they show obvious differences in key features characteristic of HD. While YAC128 mice exhibit significant and widespread accumulation of mHTT striatal aggregates, these mHTT aggregates are absent in BACHD mice. Furthermore, the levels of several striatally enriched mRNA for genes, such as DARPP-32, enkephalin, dopamine receptors D1 and D2 and cannabinoid receptor 1, are significantly decreased in YAC128 but not BACHD mice. These findings may reflect sequence differences in the human mHTT transgenes harboured by the BACHD and YAC128 mice, including both single nucleotide polymorphisms as well as differences in the nature of CAA interruptions of the CAG tract. Our findings highlight a similar profile of HD-like behavioural and neuropathological deficits and illuminate differences that inform the use of distinct endpoints in trials of therapeutic agents in the YAC128 and BACHD mice.


Subject(s)
Huntington Disease/genetics , Nerve Tissue Proteins/genetics , Neurons/metabolism , Animals , Disease Models, Animal , Female , Huntingtin Protein , Huntington Disease/metabolism , Huntington Disease/pathology , Male , Mice , Mice, Transgenic , Nerve Tissue Proteins/metabolism , Neurons/pathology , Transgenes
10.
Behav Neurosci ; 125(6): 911-20, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22122152

ABSTRACT

Syrian hamsters readily form dominant-subordinate relationships under laboratory conditions. Winning or losing in agonistic encounters can have striking, long-term effects on social behavior, but the mechanisms underlying this experience-induced behavioral plasticity are unclear. The present study tested the hypothesis that changes in brain-derived neurotrophic factor (BDNF) may at least in part mediate this plasticity. Male hamsters were paired for 15-min using a resident-intruder model, and individuals were identified as winners or losers on the basis of their behavior. BDNF was examined with in situ hybridization 2 hr after treatment during the consolidation period of emotional learning. Losing animals had significantly more BDNF mRNA in the basolateral (BLA) and medial (MeA) nuclei of the amygdala when compared with winning animals as well as novel cage and home cage controls. Interestingly, winning animals had significantly more BDNF mRNA in the dentate gyrus of the dorsal hippocampus than did losing animals, novel, and home cage controls. No conflict-related changes in BDNF mRNA were observed in several other regions including the bed nucleus of the stria terminalis and central amygdala. Next, we demonstrated that K252a, a Trk receptor antagonist, significantly reduced the acquisition of conditioned defeat when administered within the BLA. These data support a model in which BDNF-mediated plasticity within the BLA supports learning of submission or subordinate social status in losing animals, whereas BDNF-mediated plasticity within the hippocampus may instantiate aspects of winning such as control of a territory in dominant animals.


Subject(s)
Aggression/physiology , Brain-Derived Neurotrophic Factor/biosynthesis , Gene Expression Regulation , Limbic System/metabolism , Social Behavior , Stress, Psychological/metabolism , Territoriality , Aggression/psychology , Amygdala/metabolism , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/physiology , Cricetinae , Male , Mesocricetus , Neuronal Plasticity/physiology , Stress, Psychological/psychology
11.
Proc Natl Acad Sci U S A ; 108(29): 12101-6, 2011 Jul 19.
Article in English | MEDLINE | ID: mdl-21730160

ABSTRACT

Emerging genetic and clinical evidence suggests a link between Gaucher disease and the synucleinopathies Parkinson disease and dementia with Lewy bodies. Here, we provide evidence that a mouse model of Gaucher disease (Gba1(D409V/D409V)) exhibits characteristics of synucleinopathies, including progressive accumulation of proteinase K-resistant α-synuclein/ubiquitin aggregates in hippocampal neurons and a coincident memory deficit. Analysis of homozygous (Gba1(D409V/D409V)) and heterozygous (Gba1(D409V/+) and Gba1(+/-)) Gaucher mice indicated that these pathologies are a result of the combination of a loss of glucocerebrosidase activity and a toxic gain-of-function resulting from expression of the mutant enzyme. Importantly, adeno-associated virus-mediated expression of exogenous glucocerebrosidase injected into the hippocampus of Gba1(D409V/D409V) mice ameliorated both the histopathological and memory aberrations. The data support the contention that mutations in GBA1 can cause Parkinson disease-like α-synuclein pathology, and that rescuing brain glucocerebrosidase activity might represent a therapeutic strategy for GBA1-associated synucleinopathies.


Subject(s)
Gaucher Disease/pathology , Glucosylceramidase/metabolism , Hippocampus/enzymology , alpha-Synuclein/metabolism , Analysis of Variance , Animals , Blotting, Western , Dependovirus , Endopeptidase K/metabolism , Gaucher Disease/metabolism , Gene Transfer Techniques , Genetic Vectors/genetics , Glucosylceramidase/genetics , Hippocampus/cytology , Immunohistochemistry , Mice
12.
Sci Transl Med ; 3(72): 72ra18, 2011 Mar 02.
Article in English | MEDLINE | ID: mdl-21368223

ABSTRACT

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations in the SMN1 gene that result in a deficiency of SMN protein. One approach to treat SMA is to use antisense oligonucleotides (ASOs) to redirect the splicing of a paralogous gene, SMN2, to boost production of functional SMN. Injection of a 2'-O-2-methoxyethyl-modified ASO (ASO-10-27) into the cerebral lateral ventricles of mice with a severe form of SMA resulted in splice-mediated increases in SMN protein and in the number of motor neurons in the spinal cord, which led to improvements in muscle physiology, motor function and survival. Intrathecal infusion of ASO-10-27 into cynomolgus monkeys delivered putative therapeutic levels of the oligonucleotide to all regions of the spinal cord. These data demonstrate that central nervous system-directed ASO therapy is efficacious and that intrathecal infusion may represent a practical route for delivering this therapeutic in the clinic.


Subject(s)
Muscular Atrophy, Spinal/genetics , Muscular Atrophy, Spinal/pathology , Muscular Atrophy, Spinal/therapy , Oligonucleotides, Antisense/therapeutic use , Spinal Cord/pathology , Animals , Disease Models, Animal , Drug Delivery Systems , Humans , Macaca fascicularis , Mice , Motor Neurons/physiology , Muscular Atrophy, Spinal/physiopathology , Neuromuscular Junction/ultrastructure , Oligonucleotides, Antisense/administration & dosage , Oligonucleotides, Antisense/genetics , Oligonucleotides, Antisense/pharmacokinetics , RNA Splicing , Spinal Cord/physiopathology , Survival of Motor Neuron 1 Protein/genetics , Survival of Motor Neuron 2 Protein/genetics
13.
Peptides ; 27(8): 2005-11, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16774797

ABSTRACT

CART is a neuropeptide that appears to play an important role in a variety of physiological processes. The major research focus into the function of CART peptide has been on feeding behavior, modulation of mesolimbic dopamine, and actions of psychostimulant drugs. The neuroanatomic expression profile of CART does however suggest other functions as well, and its presence within the limbic system points to a possible role in emotionality. There are now several published reports which describe a new role for CART as a mediator of anxiety-like behaviors in rodents. This review will summarize these findings and speculate on the mechanisms by which CART might be involved in the modulation of these behaviors. We will also consider what future studies need to be done to further clarify the role of this peptide in anxiety.


Subject(s)
Anxiety/metabolism , Nerve Tissue Proteins/metabolism , Animals , Anxiety/physiopathology , Behavior, Animal/drug effects , Behavior, Animal/physiology , Brain/anatomy & histology , Brain/drug effects , Brain/metabolism , Dopamine/metabolism , Models, Biological , Nerve Tissue Proteins/pharmacology , Nerve Tissue Proteins/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...